Multiple imaging advocates, notably SNMMI, have been calling on the federal agency to update its policies and require amyloid results prior to starting treatment with Aduhelm.

The Society of Nuclear Medicine & Molecular Imaging says such scans are key for diagnosing the disease and will be monitoring the administration's findings.

The agency now recommends Aduhelm only for patients in the early stages of the disease, more closely aligning with the population tested during clinical trials.

Leading experts say there is no clinical evidence the controversial drug can help patients with cerebral amyloid angiopathy, a condition similar to Alzheimer's disease.

Koch Disruptive Technologies led this series C-5 effort, with others including Fidelity Management & Research Company and Baillie Gifford also chipping in.

Frank Scholz, PhD, will oversee the Beloit, Wisconsin, firm's Mo-99 expansion efforts and new radioisotope development programs, among other duties.

General Electric's $18 billion healthcare arm anticipates physicians will require more doses of its Vizamyl F18-PET agent, used to diagnose beta-amyloid plaques in the brain. 

Abdominal aortic aneurysms typically remain asymptomatic until they burst, making earlier detection and treatment high priorities for physicians.